Investigating how EGFR signaling affects glioblastoma growth and invasion
Bimodal EGFR signaling in glioblastoma
This study is looking at how a protein called EGFR affects glioblastoma, a common brain cancer, to find new ways to treat it better, including testing a drug that might help slow down the tumor's growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11002338 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, the most common type of brain cancer in adults, and how the epidermal growth factor receptor (EGFR) influences tumor behavior. It aims to understand the dual roles of EGFR signaling, where one pathway promotes tumor invasion while another, activated by specific ligands, suppresses it. The study will explore the mechanisms behind these effects and identify potential therapeutic targets, including the drug tofacitinib, which may enhance the tumor-suppressive functions of EGFR. By examining these pathways, the research seeks to improve treatment strategies for glioblastoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma, particularly those with EGFR amplification.
Not a fit: Patients with glioblastoma who do not have EGFR amplification or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that effectively reduce glioblastoma invasion and improve patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting EGFR signaling pathways in glioblastoma, indicating that this approach has potential for success.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Habib, Amyn — Ut Southwestern Medical Center
- Study coordinator: Habib, Amyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.